ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on X

Kidney Week

Educational Symposium

Cytokines and IgA Nephropathy: Pathogenesis and Novel Therapies

November 04, 2023 | 12:45 PM - 01:45 PM

Location: Grand Ballroom Salon A, Level 5, Philadelphia Marriott Downtown

Session Description

Despite remaining the most common primary glomerulonephritis worldwide, there are very few treatment options for IgA nephropathy (IgAN). The US Food and Drug Administration recently approved novel immunosuppressive and nonimmunosuppressive therapies for IgAN, and there are many more targeted therapeutic options on the horizon.

The "four-hit hypothesis" regarding the pathogenesis of IgAN centers on formation of anti-galactose-deficient IgA1 (Gd-IgA1) antibodies, deposition of the immune complexes in the glomerulus, and subsequent inflammation causing glomerulonephritis. B cell activating factor (BAFF) and A proliferation-inducing ligand (APRIL) are cytokines that maintain the B cell pool. BAFF and APRIL levels are increased in patients with IgAN and correlate with gd-IgA1 levels. Thus, therapies targeting Gd-IgA1 antibody production via BAFF or APRIL may offer a novel treatment option for patients with IgAN.

Support is provided by an educational grant from Otsuka America Pharmaceutical, Inc.

Learning Objective(s)

  • Explain the significance of BAFF and APRIL in the pathogenesis of IgAN
  • Discuss emerging therapies targeting BAFF and APRIL in IgAN

Learning Pathway(s)

  • Glomerular Diseases